Yann Mazabraud - Mar 19, 2024 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role: EVP, Head of International
Signature: /s/ Hunter Smith, attorney-in-fact for Yann Mazabraud
Stock symbol: RYTM
Transactions as of: Mar 19, 2024
Transactions value $: -$627,520
Form type: 4
Date filed: 3/19/2024, 08:53 PM
Previous filing: Feb 21, 2024
Next filing: Apr 16, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RYTM	Common Stock	Sale	-$628K	-16K	-39.51%	$39.22	24.5K	Mar 19, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $39.10 to $39.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $39.10 to $39.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.